Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
SYS-CON.TV
immatics Appoints Peter Chambré as Chairman

TUEBINGEN, Germany, November 12, 2012 /PRNewswire/ --

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced the appointment of Peter Chambré as Chairman of the Board with immediate effect. Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry. He will replace Thomas Widmann, who has been Chairman of the Company since 2004.

Peter Chambré was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006. Before joining CAT, Peter Chambré was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc, a drug delivery company.

Following these major executive roles in the sector, Peter Chambré has held several Chairman and Non-executive Director positions. From 2008-2010, he was Chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter Inc. in March 2010, and from 2006-2012, Non-executive Director of BTG plc. Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies.

Paul Higham, CEO of immatics, said: "I am delighted to welcome Peter as our new Chairman. We are approaching a crucial period at immatics, and Peter's experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximize returns to our investors."

Peter Chambré said: "immatics' vaccines, based on the Company's highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials. With IMA901, immatics' lead multi-peptide based vaccine now in phase 3 development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company. On behalf of immatics, I would like to express my thanks to Thomas Widmann for his very significant contribution to the development of the Company over the past 8 years. I very much look forward to working with the Board and management, as immatics aims to improve outcomes for cancer patients and create value for all its stakeholders."

For additional information on immatics please visit http://www.immatics.com or contact:

About immatics

immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer. immatics' lead product, IMA901, is in a pivotal phase 3 study after completing a successful randomized phase 2 trial in renal cell carcinoma. immatics' pipeline also includes IMA910, which has reported improved overall survival data in patients with advanced colorectal cancer (phase 1/2 study completed), and IMA950, which is in phase 1 in patients with glioma.

immatics' unique technology platform XPRESIDENT[TM] discovers novel relevant cancer antigens known to be expressed on tumor cells, tumor-associated peptides (TUMAPs), as the basis for its vaccines. In contrast to widely used existing in silico and indirect methods to identify peptide antigens immatics' TUMAPs are confirmed to be naturally expressed in primary cancer tissue. TUMAPs activate white blood cells (so called cytotoxic T cells) against tumor cells.

immatics' vaccines contain multiple TUMAPs to maximize the chances of clinical success by increasing the number of targets on cancer cells that they address. Phase 2 results with IMA901 and IMA910 have shown significantly better survival in patients who respond to multiple TUMAPs in both of these vaccines.

immatics' multi-peptide vaccines are 'drug like', i.e. fully synthetic, off-the-shelf, easily scalable and stable.

immatics is based in Tuebingen and Martinsried (Munich), Germany.

Paul Higham, CEO
Dr. Nikola Wiegeler, Assistant to the Management
immatics biotechnologies GmbH
Phone: +49-7071-5397-110
E-mail: media@immatics.com

Citigate Dewe Rogerson
David Dible / Chris Gardner / Sita Shah
Phone: +44(0)207-638-9571
E-mail: david.dible@citigatedr.co.uk

SOURCE immatics

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
With Cloud Foundry you can easily deploy and use apps utilizing websocket technology, but not everybody realizes that scaling them out is not that trivial. In his session at 21st Cloud Expo, Roman Swoszowski, CTO and VP, Cloud Foundry Services, at Grape Up, will show you an example of...
In his session at 20th Cloud Expo, Scott Davis, CTO of Embotics, discussed how automation can provide the dynamic management required to cost-effectively deliver microservices and container solutions at scale. He also discussed how flexible automation is the key to effectively bridging...
IT organizations are moving to the cloud in hopes to approve efficiency, increase agility and save money. Migrating workloads might seem like a simple task, but what many businesses don’t realize is that application migration criteria differs across organizations, making it difficult f...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The wide...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a r...
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process t...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021


SYS-CON Featured Whitepapers
ADS BY GOOGLE